The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A new 5-gene signature predictive of risk of relapse in early breast cancer.
Giorgio Mustacchi
Consultant or Advisory Role - AlphaGenics
Honoraria - Celgene; Novartis; Roche
Research Funding - AlphaGenics
Luca Morandi
No relevant relationships to disclose
Mariapia Sormani
No relevant relationships to disclose
Alessandra Gennari
No relevant relationships to disclose
Fabrizio Zanconati
No relevant relationships to disclose
Daniela Bonifacio
No relevant relationships to disclose
Adriana Monzoni
Employment or Leadership Position - AlphaGenics
Paolo Bruzzi
No relevant relationships to disclose